Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Relay Therapeutics (RLAY) over the last 6 years, with Q2 2025 value amounting to 10424.82%.

  • Relay Therapeutics' EBITDA Margin changed N/A to 10424.82% in Q2 2025 from the same period last year, while for Sep 2025 it was 3585.56%, marking a year-over-year decrease of 1945500.0%. This contributed to the annual value of 3382.66% for FY2024, which is 20840300.0% down from last year.
  • Latest data reveals that Relay Therapeutics reported EBITDA Margin of 10424.82% as of Q2 2025.
  • Relay Therapeutics' EBITDA Margin's 5-year high stood at 8030500.0% during Q4 2023, with a 5-year trough of 83011.76% in Q2 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 12090.65% (2021), whereas its average is 517189.41%.
  • In the last 5 years, Relay Therapeutics' EBITDA Margin tumbled by 2000000000bps in 2021 and then surged by 2000000000bps in 2023.
  • Over the past 5 years, Relay Therapeutics' EBITDA Margin (Quarter) stood at 12090.65% in 2021, then tumbled by -111bps to 25507.51% in 2022, then surged by 31583bps to 8030500.0% in 2023, then plummeted by -100bps to 822.91% in 2024, then crashed by -1167bps to 10424.82% in 2025.
  • Its last three reported values are 10424.82% in Q2 2025, 990.18% for Q1 2025, and 822.91% during Q1 2024.